NFE2L2 and lung carcinoma: It has also been found that Keap1/Nrf2 mutation status predicts the risk of local recurrence after radiotherapy in NSCLC patients, and Keap1/Nrf2 mutant lung cancers may be radiotherapy resistant to radaition due to enhanced expression of ROS clearance and detoxification pathways (Jeong et al., 2017).